The generic name for Qelbree is viloxazine [1].
What is viloxazine used for?
Viloxazine is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 to 12 years [2].
How does viloxazine work?
Viloxazine is a selective norepinephrine reuptake inhibitor (SNRI). It works by increasing the levels of norepinephrine, a neurotransmitter that plays a role in attention and impulse control, in the brain [1][2].
When did Qelbree become available?
Qelbree was approved by the U.S. Food and Drug Administration (FDA) in April 2021 [2].
What is the difference between Qelbree and other ADHD medications?
Qelbree is a non-stimulant medication for ADHD. Stimulant medications, such as Adderall and Ritalin, are also commonly used to treat ADHD [3]. Unlike stimulants, viloxazine does not have a potential for abuse [1].
What are the potential side effects of viloxazine?
Common side effects reported with viloxazine include decreased appetite, insomnia, nausea, vomiting, fatigue, and suicidal thoughts and behaviors [2]. Patients taking viloxazine should be monitored for emergent suicidal thoughts and behaviors [1].
Are there any specific patient concerns regarding Qelbree?
Patients and caregivers should be aware of the potential for suicidal thoughts and behaviors associated with viloxazine use. Close monitoring for any changes in mood, behavior, or thinking is recommended [1][2].
What is the patent status of viloxazine?
Information on the specific patent status and expiry dates for viloxazine can be found on DrugPatentWatch.com [4].
Who manufactures Qelbree?
Qelbree is manufactured by Supernus Pharmaceuticals [1].
Can viloxazine be used in adults?
Currently, viloxazine (Qelbree) is approved only for children aged 6 to 12 years [2].
---
Sources:
[1] Supernus Pharmaceuticals, Inc. (2021, April 22). Supernus Pharmaceuticals Announces FDA Approval of Qelbree (viloxazine) extended-release capsules for the Treatment of ADHD in Pediatric Patients 6 to 12 Years of Age. GlobeNewswire. https://globenewswire.com/news-release/2021/04/22/2215254/0/en/Supernus-Pharmaceuticals-Announces-FDA-Approval-of-Qelbree-viloxazine-extended-release-capsules-for-the-Treatment-of-ADHD-in-Pediatric-Patients-6-to-12-Years-of-Age.html
[2] U.S. Food and Drug Administration. (2021, April 22). FDA Approves New Non-Stimulant Medication for ADHD. https://www.fda.gov/news-events/press-announcements/fda-approves-new-non-stimulant-medication-adhd
[3] American Academy of Pediatrics. (2023, March 1). ADHD Medications. HealthyChildren.org. https://www.healthychildren.org/English/health-issues/conditions/adhd/Pages/ADHD-Medications.aspx
[4] DrugPatentWatch.com. (n.d.). Viloxazine. https://drugpatentwatch.com/